Abstract
Clinical practice has shown that Parkin is the major causative gene found in an autosomal recessive juvenile parkinsonism (AR-JP) via Parkin mutations and that the Parkin protein is the core expression product of the Parkin gene, which itself belongs to an E3 ubiquitin ligase. Since the discovery of the Parkin gene in the late 1990s, researchers in many countries have begun extensive research on this gene and found that in addition to AR-JP, the Parkin gene is associated with many diseases, including type 2 diabetes, leprosy, Alzheimer's, autism, and cancer. Recent studies have found that the loss or dysfunction of Parkin has a certain relationship with tumorigenesis. In general, the Parkin gene, a well-established tumor suppressor, is deficient and mutated in a variety of malignancies. Parkin overexpression inhibits tumor cell growth and promotes apoptosis. However, the functions of Parkin in tumorigenesis and its regulatory mechanisms are still not fully understood. This article describes the structure, functions, and post-translational modifications of Parkin, and summarizes the recent advances in the tumor suppressive function of Parkin and its underlying mechanisms.
Introduction: The Shift from Neurology to Oncology
For decades, Parkin (encoded by the PARK2 gene) was primarily categorized as a neurology-specific protein. Mutations in this gene are the leading cause of autosomal recessive juvenile parkinsonism. However, a significant shift in research has occurred as scientists noticed that the chromosomal region housing Parkin (6q25.2-q27) is frequently deleted or mutated in a wide array of cancers, including lung, breast, and ovarian malignancies.
Parkin acts as a complex E3 ubiquitin ligase—a molecular "tagger" that marks other proteins for destruction or relocation. Its activity is not a simple binary state; rather, it is finely tuned by various cellular signals. This review synthesizes how post-translational modifications (PTMs)—the chemical "software updates" of the protein world—act as the primary control knobs for Parkin's ability to stifle cancer through distinct biological pathways.
Structural Architecture of Parkin
To understand how Parkin is regulated, one must first look at its complex structural domains. Parkin consists of an N-terminal ubiquitin-like (UBL) domain and a C-terminal RBR (RING-between-RING) domain, which includes RING0, RING1, IBR (in-between-RING), REP (repressor element of Parkin), and RING2 domains.
These domains allow Parkin to act as a cellular "Quality Control Officer." Beyond its well-known role in clearing damaged mitochondria (mitophagy), Parkin identifies misfolded proteins that would otherwise cause proteotoxic stress, a common driver of both neurodegeneration and cancer.
PTMs as Regulatory Switches
The activity and localization of Parkin are dictated by five key post-translational modifications. These modifications alter the protein's shape and its affinity for various substrates and enzymes.
- Phosphorylation: Primarily mediated by the PINK1 kinase, this modification "primes" Parkin for activation, particularly during mitochondrial stress.
- Ubiquitination: A self-regulatory loop where Parkin can tag itself for degradation, controlling its own cellular levels.
- Sumoylation: This modification enhances Parkin’s nuclear translocation, potentially allowing it to influence gene expression directly within the nucleus.
- Neddylation: By increasing Parkin's affinity for its "delivery" enzymes (E2s), neddylation significantly boosts its ligase activity.
- S-Nitrosylation: A complex modification involving nitric oxide that can either activate or inhibit Parkin depending on the specific cellular context and oxidative environment.
Multi-Pronged Defense Against Tumorigenesis
Parkin does not stop cancer through a single pathway; it employs a multi-pronged defense strategy. Genomic data from sources like cBioportal show that Parkin mutations or deletions are present in approximately 5% of cervical and lung squamous cell carcinomas and 2%–6% of colorectal cancers. When functional, Parkin inhibits tumors through several mechanisms:
- Apoptosis Promotion: Parkin targets and degrades anti-apoptotic proteins like Mcl-1, effectively triggering programmed cell death in damaged cells.
- Cell Cycle Arrest: It regulates CDK6 mRNA levels to halt uncontrolled cell division, acting as a brake on proliferation.
- Anti-Metastasis: By stabilizing microtubules, Parkin helps maintain cell structure and prevents the migration of cancer cells.
- Anti-Angiogenesis: In glioma studies, Parkin expression was shown to lower levels of VEGFR-2 (a key growth factor receptor for blood vessels) by nearly 4-fold, starving tumors of their blood supply.
- Inflammatory Control: Parkin-deficient cells show an abnormal increase in pro-inflammatory markers like IL-1β and TNF-α. Parkin normally dampens this chronic inflammation, which is a known precursor to malignancy.
Limitations and Future Outlook
While the regulatory role of PTMs is clear, the hierarchy of these modifications remains a mystery. It is currently unknown if certain modifications, such as phosphorylation, always override others like sumoylation in a tumor environment.
Future research must focus on developing small molecules that can mimic "activating" PTMs (like neddylation) to restore Parkin function in cancer cells. Additionally, understanding why certain modifications like S-nitrosylation have dual roles will be critical. Ultimately, Parkin PTM profiles may serve as vital biomarkers to predict patient responses to specific chemotherapies, such as paclitaxel.
Summary updated